What to know as first FDA-approved GLP-1 pill for weight loss heads for pharmacies

Key Concepts

• GLP-1 Receptor Agonists: A class of medications originally developed for type 2 diabetes, now used for weight loss, mimicking the effects of the naturally occurring GLP-1 hormone.
• WGOI: The newly FDA-approved oral pill version of a GLP-1 receptor agonist for obesity treatment.
• Subcutaneous Injection: Administration of a drug under the skin, allowing for slower, more consistent absorption.
• Compounded Medications: Drugs created by mixing ingredients by a pharmacist, often not subject to the same rigorous FDA approval process as manufactured drugs.
• Efficacy: The ability of a treatment to produce a desired or intended result.

FDA Approval of Oral WGOI & GLP-1 Medications: A Detailed Overview

The Food and Drug Administration (FDA) recently approved WGOI, the first daily oral medication specifically for treating obesity. This marks a significant advancement as previous GLP-1 receptor agonists required injection. Dr. Holly Loftton, operating a medical weight management program at NYU Health First, discussed the implications of this approval and related issues.

Efficacy Comparison: Pill vs. Injection

While the oral pill version of the GLP-1 agonist is effective, it demonstrates slightly lower efficacy compared to injectable formulations. Injectable GLP-1s typically result in 20-23% weight loss for patients. In contrast, WGOI, the oral pill, achieves weight loss in the range of 14-17%. Dr. Loftton emphasized that even this lower percentage represents a “significant amount of weight loss.”

Pharmacokinetic Differences: Oral vs. Subcutaneous Administration

The difference in efficacy stems from the method of administration. Injectable GLP-1s are administered subcutaneously – under the skin – allowing for slow and sustained absorption over a week. This bypasses initial metabolic processes. Oral medications, like WGOI, are absorbed through the stomach and liver. This process reduces the drug’s effectiveness due to decreased absorption, a consequence of the GLP-1 receptor agonists being “large molecules.” The liver metabolizes a portion of the drug before it can reach systemic circulation, diminishing its impact.

FDA-Approved vs. Compounded GLP-1s

The discussion addressed the growing availability of compounded GLP-1 medications offered by health startups like HIMS and Hers. Dr. Loftton stressed a critical distinction: FDA-approved medications, such as WGOI, undergo “stringent facility…evaluations” to ensure both safety and efficacy. Compounded medications, however, do not face the same level of FDA scrutiny. Consequently, their safety and effectiveness are not guaranteed. The FDA approval process involves rigorous testing and quality control measures absent in compounding pharmacies.

GLP-1s and Alcohol Consumption

Dr. Loftton addressed the observed effects of GLP-1s on alcohol consumption, particularly relevant during “Dry January.” While not officially approved for substance abuse treatment, individuals taking GLP-1s frequently report a decreased desire to drink alcohol. This is attributed to alcohol becoming “less pleasurable,” with some experiencing nausea or increased sensitivity to alcohol’s effects even at smaller quantities. This side effect is often perceived as a positive outcome by patients.

Concluding Remarks

The FDA approval of WGOI represents a significant step forward in obesity treatment, offering a convenient oral alternative to injections. While slightly less potent, the pill still provides substantial weight loss benefits. However, it’s crucial to differentiate between FDA-approved medications and compounded versions, prioritizing safety and efficacy. The observed impact of GLP-1s on alcohol consumption presents an interesting, though currently unapproved, potential benefit.